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Abstract: Purpose: To investigate the frequency, localization, and survival of second primary tumors
(SPT) of oropharyngeal squamous cell carcinoma (OPSCC) depending on human papillomavirus (HPV)
status. Methods: We performed a retrospective chart analysis of 107 OPSCC patients treated at the
Zurich University Hospital from 2001 to 2010. Rate and localization of SPT after an index OPSCC
were stratified according to smoking and HPV infection status. Results: In total, 57/91 (63%) included
patients showed an HPV-associated OPSCC. Of these, 37/57 (64.9%) patients with an HPV-positive
and 32/34 (94.1%) patients with an HPV-negative OPSCC were smokers. The median age at diagnosis
of the SPT was 59.54 years (interquartile range 52.7–65.6). In addition, 8/57 (14%) HPV-positive and
13/34 (38.2%) HPV-negative patients developed SPT. The rate of SPT in patients with HPV-positive
index tumors was significantly lower than in patients with HPV-negative OPSCC (p-value 0.01). Smokers
showed significantly more SPT in the head and neck area than outside. The development of an SPT led
to a significantly lower survival time in HPV-negative patients, while it did not significantly affect the
survival time of HPV-positive patients. Conclusions: Patients with HPV-positive index tumors had a
significantly lower risk of developing SPT than patients with HPV-negative tumors. If SPT developed,
survival was significantly shorter in patients with HPV-negative tumors than with HPV-positive tumors.
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Simple Summary: Human papillomavirus (HPV) infection, smoking, and excessive alcohol con-
sumption have been established as risk factors for the development of oropharyngeal squamous
cell carcinoma (OPSCC). While the HPV epidemic has led to an increasing incidence of OPSCC,
HPV-negative OPSCC cases associated with smoking and alcohol remain stable. As HPV-positive and
-negative OPSCC present two distinct etiological, clinical, and prognostic entities, different treatment
and follow-up strategies are being discussed. Still, specific surveillance strategies for HPV-positive
OPSCC are lacking, as the risk of second primary tumors (SPT) in the era of HPV-associated OPSCC
has not been comprehensively assessed. Our study investigated the frequency and localization of
SPT of HPV-positive OPSCC, as well as their prognostic impact. We find that the SPT of HPV-positive
OPSCC are less frequent than those of HPV-negative OPSCC, and they are also associated with higher
survival rates. The localization of SPT of HPV-positive OPSCC did not differ from the localization of
SPT of HPV-negative OPSCC.
Abstract: Purpose: To investigate the frequency, localization, and survival of second primary tumors
(SPT) of oropharyngeal squamous cell carcinoma (OPSCC) depending on human papillomavirus
(HPV) status. Methods: We performed a retrospective chart analysis of 107 OPSCC patients treated
at the Zurich University Hospital from 2001 to 2010. Rate and localization of SPT after an index
OPSCC were stratified according to smoking and HPV infection status. Results: In total, 57/91
(63%) included patients showed an HPV-associated OPSCC. Of these, 37/57 (64.9%) patients with an
HPV-positive and 32/34 (94.1%) patients with an HPV-negative OPSCC were smokers. The median
age at diagnosis of the SPT was 59.54 years (interquartile range 52.7–65.6). In addition, 8/57 (14%)
HPV-positive and 13/34 (38.2%) HPV-negative patients developed SPT. The rate of SPT in patients
with HPV-positive index tumors was significantly lower than in patients with HPV-negative OPSCC
(p-value 0.01). Smokers showed significantly more SPT in the head and neck area than outside.
The development of an SPT led to a significantly lower survival time in HPV-negative patients,
while it did not significantly affect the survival time of HPV-positive patients. Conclusions: Patients
with HPV-positive index tumors had a significantly lower risk of developing SPT than patients
with HPV-negative tumors. If SPT developed, survival was significantly shorter in patients with
HPV-negative tumors than with HPV-positive tumors.
Keywords: human papillomavirus; second primary; oropharyngeal squamous cell
1. Introduction
Oropharyngeal squamous cell carcinomas (OPSCC) are rare. Major risk factors for
OPSCC include excessive tobacco and alcohol consumption [1]. In 1946, Slaughter [2]
presented the model of field carcinogenesis, according to which the mucosa of the upper
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aerodigestive tract has an increased risk of oncogenic degeneration due to continuous expo-
sure to noxious agents. Based on this observation, panendoscopy (laryngopharyngoscopy,
bronchoscopy, and esophagoscopy) has been established for the workup of patients with
newly diagnosed HNSCC to detect synchronous second primary tumors (SPT) [3]. SPT
are observed in approximately 10–20% of patients with exposure to smoking or excessive
alcohol consumption [4,5].
High-risk human papillomavirus (HR-HPV) infections have been known to cause
genital tumors for about 3 decades [6]. About 2 decades ago, HPV infections were also rec-
ognized as a risk factor for OPSCC [1]. In developed countries, the incidence of all HNSCC
has decreased—possibly due to declining tobacco exposure [7]. Meanwhile, the incidence
of OPSCC has increased over the past three to four decades [8]. This specific incidence
increase can be attributed to the increasing prevalence of oncogenic HPV infections in the
oropharynx [9,10]. Thus, HPV has been identified as a new risk factor specific for OPSCC
that shows little impact on other HNSCC [11]. HPV-associated OPSCC increasingly occur
in individuals without the usual exposure to alcohol and tobacco [12].
HPV-induced OPSCC present an etiologically, molecularly, clinically, and prognos-
tically distinct entity from tobacco- and alcohol-associated OPSCC [13–16]. SPT seem to
occur less frequently in patients with HPV-positive OPSCC than in patients with HPV-
negative OPSCC [17]. Therefore, a modulation of the follow-up strategy for HPV-positive
OPSCC has to be considered.
The aim of this study was to analyze the frequency and localization as well as the
prognostic significance of SPT after index OPSCC in relation to the risk factors HPV
infection and smoking. Our research questions were the following: (i) How common
are SPT in a consecutive cohort of patients with OPSCC? (ii) Are SPT more common
in smokers than in nonsmokers? (iii) Does this frequency depend on HPV status? (iv)
Does the location of SPT differ between smokers and nonsmokers or HPV-positive and
HPV-negative patients? (v) What is the impact of the development of SPT on survival?
2. Materials and Methods
A retrospective analysis was performed using medical records of patients who were
treated in a curative intent for newly diagnosed oropharyngeal carcinoma (OPSCC) at the
Department of Otorhinolaryngology—Head and Neck Surgery at the University Hospital
Zurich (USZ), Zurich, Switzerland between 2001 and 2010.
Inclusion criteria were an index tumor in the oropharynx. Exclusion criteria on the
other hand were a non-evaluated HPV status. The starting point of observation was
the diagnosis of the index tumor. Endpoint of observation was either last follow-up
examination until January 2019 or death.
2.1. Analysis of Index Tumors
HPV positivity was determined according to an accepted algorithm [18], which in-
cludes p16 immunohistochemistry and PCR detection of HPV DNA (high-risk types).
P16-positive and HPV DNA-negative tumors were considered HPV-negative.
Furthermore, age at diagnosis of the index tumor, gender, location of the index tumor,
tobacco and alcohol consumption, occurrence of SPT, and disease progression (recurrence,
death of patients) were obtained from medical records. Death was distinguished as due
to index tumor, due to SPT, and independent of cancer. Survival rates were plotted using
Kaplan–Meier survival curves, with the start of observation being the time of diagnosis of
the index tumor.
• Smokers were defined as ≥10 pack years, regardless of the time of tobacco use.
• Alcohol abuse was defined as a history of >2 U/day for women and >3 U/day for
men, respectively, with a standard unit (U) corresponding to 10 g of pure alcohol.
• An SPT was defined as a second carcinoma in the upper aerodigestive tract, lung, or
bladder, differing in site from the index tumor, which was unlikely to be a metastasis
of the index carcinoma [19].
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• HPV types 16, 18, 33, 35, 56, and 59 were considered high-risk HPV types (HR-
HPV) [20].
Age, sex, history of alcohol abuse, recurrence of index tumor, death from OPSCC-
associated cancer, and development of second carcinomas were compared among the
following three groups of patients: (1) HPV-positive nonsmokers, (2) HPV-positive smokers,
and (3) HPV-negative patients.
2.2. Analysis of Second Tumors
Time to SPT occurrence was defined as time between diagnosis of index OPSCC and
initial diagnosis of SPT.
Frequency and location of SPT after an index OPSCC were determined in relation to
smoking and HPV status. Among SPT, synchronous tumors (detected simultaneously or
within 6 months of the index tumor diagnosis) were distinguished from metachronous
tumors (detected >6 months after the index tumor) [21]. In addition, the development of
SPT of HPV-positive and HPV-negative patients was plotted over time.
2.3. Statistics
Statistical analyses of the data were performed using Stata 13. Patient characteristics
were evaluated using T-test and Fisher’s exact test of group means controlled for unequal
variances of individual characteristics. For evaluation of statistical significance of contin-
uous variables such as age, the T-test was applied, while for discrete variables, Fisher’s
exact test was applied. Statistical significance was defined at the 5% level of significance,
i.e., p < 0.05.
To evaluate the effect of HPV status, UICC stage (Union internationale contre le
cancer), and therapy mode, age, sex, tobacco, and alcohol abuse on the development of SPT,
HPV status, and death from cancer, multivariate Cox regression analyses were performed.
For survival analysis, we used Kaplan–Meier survival curves and controlled for
significant differences between groups using log-rank tests. Additionally, a multivariate
cox regression analysis was performed to evaluate the influence of age, gender, tobacco
and alcohol abuse, HPV status, index-UICC stage, therapy mode of the index tumor, and
development of an SPT on survival.
2.4. Ethics
Ethical approval by the Zurich Ethics Committee for retrospective analysis of patient
data is available (KEK-ZH-No. 2013-0019).
3. Results
3.1. Patient Characteristics
After exclusion of 16 patients due to undefined HPV status, the analyzed cohort
consisted of 91 patients. Table 1 summarizes the patient characteristics. Follow-up of
the initial carcinoma occurred for a mean of 57.17 months (4.76 years, interquartile range
31.08–65.25 years) from diagnosis.
In total, 57/91 OPSCC (62.6%) showed p16-overexpression and positivity for HR-HPV
DNA, as detected by PCR. Therefore, these tumors were considered as HPV-positive tumors.
With 89.5% (51/57 HPV-positive tumors), HPV16 was the most frequently identified HPV
type. Other HPV types detected were HPV18, HPV 33, HPV 35, HPV 56, and HPV 59.
More than 90% of the index tumors of HPV-positive patients were located in the
tonsils, as shown in Table 1. The index tumors of HPV-negative patients were located in
the tonsil (76.5%), base of tongue (14.7%), pharyngeal wall (5.9%), and soft palate (2.9%).
The mean age of all patients with OPSCC was 59.54 years and comparable among the
three groups (HPV-positive smokers, HPV-positive nonsmokers, and HPV-negative smokers).
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Table 1. Patient characteristics. The p-values related to age are calculated by T-test (columns 5 and 6, marked in italics).
The other group comparisons of columns 5 and 6 were performed with two-sided Fisher’s exact test. Values statistically
significant at the 5% significance level are marked with *. Abbreviations: − = negative, + = positive, chemo = chemotherapy,
IQR = interquartile range, RT = radiotherapy.
Patient Characteristics
















ers (n = 69
vs. n = 22)n = 91 n = 20 n = 37 n = 34
Age at diagnosis of index tumor
Median (y) 59.54 58.2 58.7 57.6
0.483 0.646IQR 52.7–65.6 52.8–66.7 51.0–67.3 53.8–65.1
Sex
male n (%) 68 (74.7%) 14 (70%) 28 (75.7%) 26 (76.5%) 0.809 0.413
female n (%) 23 (25.3%) 6 (30%) 9 (24.3%) 8 (23.4%)
History of alcohol abuse n (%) 28 (30.8%) 0 9 (24.3%) 19 (55.9%) 0.000 * 0.000 *
Index-OPSCC
localization
Tonsils n (%) 79 (86.8%) 19 (95%) 34 (91.9%) 26 (76.6%) 0.050 * 0.281
Base of tongue n (%) 9 (9.9%) 1 (5%) 3 (8.1%) 5 (14.7%) 0.286 0.446
Soft palate n (%) 1 (1.1%) - - 1 (2.9%) - -
Pharyngeal wall n (%) 2 (2.2%) - - 2 (5.9%) - -
Death due to OPSCC or
associated cancer
n (%) 17 (18.7%) 2 (10%) 5 (13.4%) 10 (29.4%) 0.054 0.226
Index-UICC stadium
I n (%) 15 (16.5%) 3 5 7 0.56 1
II n (%) 17 (18.7%) 5 6 6 1 0.345
III n (%) 11 (12.1%) 0 4 7 0.093 0.06
IVa n (%) 47 (51.6%) 12 22 13 0.055 0.47
IVb n (%) 1 (1.1%) 0 0 1 - -
Treatment
Surgery n (%) 91 (100%) 20 (100%) 37 (100%) 34 (100%) 1 1
RT ± chemo n (%) 60 (65.9%) 13 (65%) 25 (67.6%) 21 (61.8%)
Independent of HPV status, OPSCC patients were more likely to be male (74.7%)
and smokers (72.9%). HPV-positive patients smoked significantly less than HPV-negative
patients (p-value 0.002). Only 2/34 patients with HPV-negative tumors were nonsmokers
and therefore, they were not separately analyzed.
There were no patients with history of alcohol abuse among nonsmokers, whereas
9/37 (24.3%) of the HPV-positive smokers and 19/32 (59.3%) of the HPV-negative smokers
had a history of alcohol abuse. This difference in alcohol consumption between smokers
and nonsmokers was statistically highly significant (p-value 0.0001).
3.2. Frequency of Second Primary Tumors
In the overall cohort, 21/91 (23.1%) OPSCC patients developed an SPT during the ob-
servation period (Table 2): 4 (20%) HPV-positive nonsmokers, 4 (10.8%) HPV-positive smok-
ers, and 13 (38.2%) HPV-negative patients. HPV-negative OPSCC patients developed sig-
nificantly more SPT than HPV-positive patients (p-value 0.011, Fisher’s exact test), whereas
there was no difference between HPV-positive nonsmokers and HPV-positive smokers.
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Table 2. Overview of the number and locations of SPT of HPV-positive nonsmokers, HPV-positive smokers, and HPV-
negative patients. The table compares the number of SPT, as well as the number of SPT at specific locations, between
HPV-positive and HPV-negative patients, smokers and nonsmokers, and between HPV-positive nonsmokers and HPV-
positive smokers using a two-sided Fisher’s exact test. Results statistically significant at the 5% significance level are
marked with *. Abbreviations: HPV = human papillomavirus, NS = nonsmokers, S = smokers, + = positive, − = negative,

























(n = 20 vs.
n = 37)
SPT
Yes 21 (23.1%) 4 (20%) 4 (10.8%) 13 (38.2%) 0.011 * 0.772 0.432
SPT
localization
Oral cavity 4 (4.4%) 1 (5%) 0 3 (8.8%) - - -
Oropharynx 5 (5.5%) 0 2 (5.4%) 3 (8.8%) 0.965 0.020 * 0.429
Larynx 3 (3.3%) 0 1 (2.7%) 2 (5.9%) - - -
Hypopharynx 2 (2.2%) 0 0 2 (5.9%) - - -
Esophagus 1 (1.1%) 0 0 1 (2.9%) - - -
Lung 6 (6.6%) 3 (15%) 1 (2.7%) 2 (5.9%) 0.146 0.053 0.486
Using a multivariate Cox regression analysis, we examined the influence of HPV-
positivity, smoking, alcohol, age, gender, UICC stage, and the therapy mode for the index
tumor, on the development of SPT. The results of the multivariate Cox regression are shown
in Table 3. Factors such as smoking status, alcohol abuse, age, and gender of the patients
showed no significant influence on the development of SPT in this analysis. HPV positivity,
on the other hand, was with an HR of 0.344 (95% CI 0.149–0.791, p = 0.012), which was
statistically significantly inversely correlated with the development of SPT.
Table 3. Multivariate Cox regression for SPT development. Table 3 shows the results of the multivariate Cox regression of
SPT (0 = no SPT, 1 = SPT) on the independent variables of tumor HPV positivity (negative = 0, positive = 1), smoking status
(0 = <10 py, 1 = ≥10 py), history of alcohol abuse (0 = no alcohol abuse, 1 = alcohol abuse), age (in years), sex (0 = male,
1 = female), UICC stage (1 = stage I, 2 = stage II, 3 = stage III, 4 = stage IVa, 5 = stage IVb), and therapy mode (0 = surgery only,
1 = RT ± chemo). * indicates statistical significance at the 5% significance level. Since alcohol use is unknown in three
patients, 88 observations are included instead of 91. Abbreviations: Chemo = chemotherapy, CI = confidence interval,
HR = hazard ratio, py = pack years, RT =radiotherapy, UICC = Union internationale contre le cancer.

































Number of observations 88
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3.3. Distribution of Second Primary Tumors over Time
Six of 21 (28.6%) SPT appeared synchronously with the index tumor, while 15/21
(71.4%) appeared metachronously. The synchronous SPT were located in the oropharynx
(2 SPT), hypopharynx (2 SPT), larynx (1 SPT), and lung (1 SPT).
Metachronous SPT appeared after an average of 68.9 months (range: 11–190 months,
IQR 20–101 months). The majority (60%) of the metachronous SPT was located inside the
head and neck area (Table 4): oral cavity (4 SPT), oropharynx (3 SPT), and larynx (2 SPT).
Table 4. Number of SPT in and outside the head and neck area in HPV-positive and HPV-negative
patients. The p-value compares HPV-positive and HPV-negative patients regarding SPT localization
in the head and neck area. The p-value was calculated using Fisher’s exact test.
SPT Localizations
Total






Head and neck 14 (66.7%) 4 (50%) 10 (76.9%)
0.346
outside head and neck 7 (33.3%) 4 (50%) 3 (23.1%)
One case showed a metachronous SPT in the esophagus, and 5 were located in the lung.
The number of SPT and timely distribution of SPT occurrence in relation to the HPV
status are depicted in Figure 1.
Figure 1. Distribution of SPT over time.
Metachronous SPT of HPV-positive patients occurred after an average of 91.6 months,
while the SPT of HPV-negative patients were diagnosed after 49 months on average.
Although this difference is striking, it did not reach statistical significance (p-value of 0.161,
Table 5).
Table 5. Time of occurrence of metachronous SPT.
Time of Occurrence of
Metachronous SPT (Months)
HPV-Positive
(n = 7 SPT)
HPV-Negative
(n = 8 SPT)
p-Value
Average 91.6 49
Median 90 39.5 0.161
IQR 22–154 17–77
Notably, two of the HPV-positive SPT were diagnosed after more than 12 and 15 years,
respectively (larynx and oropharynx).
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3.4. Influence of Second Primary Tumors on Survival
Overall, 17/91 (18.7%) OPSCC patients died: 2 HPV-positive nonsmokers, 5 HPV-
positive smokers, and 10 HPV-negative patients. Patients with HPV-positive OPSCC
showed significantly better disease-specific survival than patients with HPV-negative
OPSCC (5 year survival 91.2% for HPV-positive vs. 76.5% for HPV-negative patients;
p < 0.0001, Figure 2), as shown by Kaplan–Meier analysis.
Figure 2. Kaplan–Meier survival plots of HPV-positive and HPV-negative patients. (Log-rank test:
p-value = 0.037) and of patients with and without SPT (Log-rank test: p-value = 0.02).
Five out of 21 (23.8%) OPSCC patients with SPT and 12/70 (17.1%) patients without
SPT died. OPSCC patients without SPT had significantly better disease-specific survival
than OPSCC patients with SPT (5-year survival 88.5% without SPT vs. 69.2% with SPT;
Fisher’s exact test: p-value < 0.0001, Figure 2).
Out of 57 HPV-positive OPSCC patients, seven (12.3%) died from the index tumor
and eight (14%) developed an SPT from which no one died within the observation period.
There was no significant difference in survival in the HPV-positive patient group with SPT
compared to HPV-positive patients without (Log-rank test: p-value = 0.514, Figure 3).
Out of 34 HPV-negative patients, 5/21 (23.8%) died without SPT and 5/13 (38.5%)
died with SPT. The disease-specific 5-year survival rate was statistically significantly higher
in HPV-negative patients without SPT (83.3%) than in HPV-negative patients with SPT
(51.4%, Fisher’s exact test: p-value < 0.0001).
Figure 3 also shows the Kaplan–Meier survival plot of the 21 patients with SPT,
analyzed by the HPV positivity of the index tumor. There was a trend for a worse survival
in HPV-negative patients developing SPT compared to HPV-positive patients with SPT
(log-rank test: p-value = 0.054).
Interestingly, none of the patients with a SPT in the oropharynx died during the time
of observation. This stands in contrast to 23.8% deaths among patients with an SPT outside
the oropharynx. However, the difference was not statistically significant (Kaplan–Meier
survival plot in Figure 3, log-rank test: p-value 0.105).
As shown in Table 6, neither therapy mode nor UICC stage of the index tumor showed
significant influence on OPSCC-associated survival.
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Figure 3. Kaplan–Meier survival plots of HPV-positive patients with and without SPT. (Log-rank
test: p-value = 0.514), Kaplan–Meier survival plot of HPV-negative patients with and without SPT
(Log-rank test: p-value = 0.033), of HPV-negative and HPV-positive patients with SPT (Log-rank test:
p-value = 0.054), and of patients with SPT in and outside the oropharynx (Log-rank test: p-value = 0.054).
Table 6. Multivariate Cox regression for death in association with OPSCC. Table 6 shows the influence
of the following variables on death due to OPSCC and/or SPT after OPSCC: tumor HPV positivity
(negative = 0, positive = 1), smoking status (0 = <10 py, 1 = ≥10 py), alcohol status (0 = no alcohol
abuse, 1 = alcohol abuse), age (in years), SPT development (0= no SPT, 1 = SPT), therapy mode
(1 = surgery, 2 = RT, 3 = surgery + RT, 4 = surgery + RT + chemotherapy, 5 = surgery + chemotherapy),
and UICC stage of the index OPSCC (1 = stage I, 2 = stage II, 3 = stage III, 4 = stage IVa, 5 = stage
IVb). Abbreviations: CI = confidence interval, HR = hazard ratio, py = pack years, RT = radiotherapy.
Multivariate Cox Regression for
Death Associated with OPSCC

































Number of observations 88
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4. Discussion
SPT of HPV-associated OPSCC have been investigated in search of optimal diagnostic
workup strategies [22,23]. As shown by Hsu et al. [24], SPT present a major obstacle
improving the long-term survival of patients with OPSCC. Therefore, SPT are of imminent
importance to follow-up of OPSCC patients. Still, to our knowledge, this is the first
study investigating the long-term survival of HPV-positive OPSCC patients with and
without SPT.
Our study compares the frequency, localization, and timely distribution of SPT devel-
opment in HPV-positive and HPV-negative OPSCC patients. Additionally, a comprehen-
sive analysis of the influence of risk factors on SPT development and SPT localization is
given. We report a significantly lower rate of SPT in HPV-positive OPSCC compared to
HPV-negative OPSCC. Our survival analysis showed a significantly negative impact of
SPT on survival in HPV-negative patients, while it did not significantly affect the survival
time of HPV-positive patients. Due to the small number of SPT, especially in the cohort of
HPV-positive patients, no firm conclusions on SPT localization can be made.
The focus of the latest research on HPV-associated OPSCC has been on possible
therapy modifications [25]. With the presented results, we hope to extend the discussion to
follow-up protocol for HPV-positive OPSCC patients.
4.1. Patient Characteristics
The three main risk factors for OPSCC are smoking, alcohol abuse, and HPV infec-
tion [26]. Indicating the impact of HPV infections, our cohort showed 63% HPV-associated
OPSCC. Older literature had found HPV-associated OPSCC to be present in a group of
patients who are younger than HPV-negative OPSCC patients and have less exposure
to noxious agents. [12]. However, more recent results from the US show a “modera-
tion of increasing incidence in younger individuals and a shift in the burden to older
individuals” [27]. Consistent with the increasing number of HR-HPV infections in the
oropharynx [8], HPV-positive nonsmokers (all without alcohol abuse) accounted for a
remarkable 22% of our cohort. In addition, HPV-positive patients smoked significantly
less than HPV-negative patients. The fraction of smokers among HPV-negative OPSCC
patients was high at 94.1%. Excessive alcohol consumption was only found in smokers
and was more prevalent in HPV-negative patients. The association of heavy tobacco and
alcohol abuse is well known in the literature [28].
Contrary to other studies [13,29], in our study cohort, HPV-positive patients were not
younger than HPV-negative patients.
4.2. Localization of Index Tumors
Consistent with literature [30,31], the vast majority of HPV-positive index OPSCC in
our cohort was located in the tonsils (93%) and the base of the tongue (7%). This supports
the suggestion of the predilection of HPV-associated tumors in the lymphoid tissue of
Waldeyer’s ring [32–34].
In contrast, HPV-negative patients showed a broader distribution with index tumors
in tonsil (76.6%), base of tongue (14.7%), pharyngeal wall (5.9%), and soft palate (2.9%).
4.3. Frequency and Localization of Second Primary Tumors
In this study, the definition of SPT was based on Warren and Gates [19], even though
the latest and more exact definition of SPT goes back to Braakhuis et al. [35]. Due to the
retrospective nature of this study, data on genetic patterns of the SPT were not available.
Therefore, the genetic differentiation of SPT from recurrence and metastasis, as suggested by
Braakhuis et al. [35], was not applicable. Table 7 provides an overview over the localization
and histology of all SPT in our cohort.
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Localization SPT Histology of SPT
Positive tonsil lung
Squamous cell carcinoma, with growth pattern
distinct from index tumor
Tonsil Lung Squamous cell carcinoma
Base of tongue (right) Vallecula (left) Squamous cell carcinoma
Base of tongue Lung Small cell lung carcinoma
Oropharynx Lung Squamous cell carcinoma
Tonsil Vocal cord Squamous cell carcinoma
Tonsil Side of the tongue Squamous cell carcinoma
Tonsil (left) Tonsil (right) unknown
Negative Oropharynx Thyroid gland Papillary thyroid carcinoma
Oropharynx Side of the tongue Squamous cell carcinoma, p16-negative
Oropharynx Lung adenocarcinoma
Tonsil Base of tongue Squamous cell carcinoma, p16-negative
Tonsil (right) Vallecula (left) Squamous cell carcinoma
Oropharynx Soft palate High grade dysplasia
Base of tongue (right) Larynx (left) Squamous cell carcinoma
Tonsil (left) Hypopharynx (right) Squamous cell carcinoma
Tonsil Lung Squamous cell carcinoma
Tonsil Hypopharynx Squamous cell carcinoma
Tonsil (right) Tonsil (left) Squamous cell carcinoma (p16-positive)
Tonsil Hypopharynx Squamous cell carcinoma
Tonsil Esophagus Squamous cell carcinomas/adeno
As hypothesized, HPV-positive patients developed significantly fewer SPT (15.79%)
than HPV-negative patients (38.24%) [17,21,36]. Similarly, Martel et al. [15] performed a
study with 412 OPSCC patients, including T and N category as additional risk factors, and
they found only HPV status showing a significant impact on the occurrence of SPT. The
authors found a 4.5-fold increased risk of developing SPT in HPV-positive patients with
heavy abuse of noxious agents or HPV-negative patients with moderate or no abuse of
noxious agents, compared with HPV-positive patients without exposure to noxious agents.
The risk of HPV-negative patients with severe noxious exposure was even increased
by a factor of 13.2 compared with HPV-positive patients without exposure to extrinsic
carcinogens. This illustrates the lower SPT risk of HPV-positive OPSCC, even with the
influence of tobacco/alcohol abuse.
Contrary to expectations, we did not find a significantly increased incidence of SPT in
smokers compared to nonsmokers, even with statistical control for age, sex, HPV status,
and alcohol abuse (Table 3). Putting this result into perspective, Table 8 showed a significant
influence of smoking on the occurrence of SPT in the head and neck area. We attributed the
nonsignificant influence of smoking on SPT development in Table 3 to the small number of
cases in our cohort. Milliet et al. [36] found alcohol and tobacco consumption, as well as a
negative HPV status to be significant predictors for SPT development in OPSCC patients.
In a literature review of the last 40 years (1979–2019), Coca-Pelaz et al. [5] found that
SPT after HNSCC occurred most frequently in the head and neck region, followed by lung
and esophagus. In our cohort, the head and neck area and the lung were also the most
common location of SPT. The same distribution was shown for HPV-positive patients,
independent of tobacco use as a risk factor. Exemplarily, an HPV-positive nonsmoker of
our cohort developed a SPT in the oral cavity. This stands in contrast to the hypothesis of
Rietbergen et al. [37] saying that SPT of HPV-positive OPSCC do not occur in the head and
neck region due to absent field carcinogenesis. They examined the tumor-free resection
margins of HPV-positive OPSCC and were unable to detect HPV16-E6 mRNA [37]. From
this, they concluded that field carcinogenesis by HPV is unlikely. McGovern et al. [38]
examined the mucosa between two adjacent HPV-positive OPSCC and were not able to
detect HPV, either.
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Table 8. Multivariate Cox regression for SPT development in the head and neck area. Table 8 describes
the results of the multivariate Cox regression of all SPT with respect to localization in the head and
neck area (0 = SPT outside head and neck, 1 = SPT in head and neck) regressed on the independent
variables tumor HPV positivity (negative = 0, positive = 1), smoking status (0 = <10 py, 1 = ≥10 py),
alcohol status (0 = no alcohol abuse, 1 = alcohol abuse), and age (in years). * indicates statistical
significance at the 5% significance level. Abbreviations: CI = confidence interval, HR = hazard ratio,
py = pack years.
Multivariate Cox Regression for SPT
Development in the Head and Neck





















Number of observations 21
In our study, HPV-positive patients mostly showed metachronous SPT. This in agree-
ment with the results of Xu et al. [23], who showed that the diagnostic workup of HPV-
positive OPSCC detected less synchronous SPT than in HPV-negative OPSCC. Thus, field
cancerization by HPV, as first described by Slaughter in 1946 [2], seems unlikely for HPV-
associated tumors.
On the basis of the clonal relationship of first and second tumors [39], Rietbergen et al. [37]
postulated that synchronous SPT of HPV-positive OPSCC result from the same infection as
the index tumor. They also deduce that SPT arise from the migration of HPV-infected cells.
A similar phenomenon has been described in women with cervical carcinoma and SPT in
the lower genital tract (vulva and vagina) [40].
In a case report of a 46-year-old patient with three synchronous HPV-associated OP-
SCC and two cervical metastases, McGovern et al. [38] also commented on the phenomenon
of multiple HPV-associated tumors. After excluding field carcinogenesis by HPV, McGov-
ern et al. postulated two models for the development of second HPV-associated lesions: (1)
multiple independent HPV infections leading to the development of multiple tumors, and
(2) a primary HPV-associated tumor producing clonally related neoplasms that migrate to
new localizations and appear as metachronous SPT.
The latter theory was supported by the findings of a case report of Joseph et al. [39],
who showed four HPV-associated carcinomas of the tonsils with molecularly identical SPTs
in the respective contralateral tonsil. In view of these data, the question arises as to the
exact delineation between SPT and metastasis. A 100% genetic match would classify for
a metastasis, even if it appeared with an exceptionally large temporal distance from the
primary tumor.
Due to the small number of HPV-positive SPT in our cohort, we could not make robust
statements on the frequency of HPV-associated SPT at individual sites. Still, the detected
localizations, especially of HPV-positive SPT, are noteworthy.
In our cohort, looking specifically at SPT in the head and neck area, tumoral HPV
positivity of the index tumor did not show any significant influence on the frequency of
SPT, while smoking and age of the patient did. Thus, the risk of SPT in the head and neck
area decreased with increasing age, while it increased in smokers.
This is consistent with the results of Peck et al. [22] who demonstrated that HPV-
seropositive patients developed proportionally fewer SPT in traditionally tobacco-associated
sites than HPV-seronegative patients. However, it is important to note that Peck et al. [22]
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determined HPV status using serum markers, which show exceptionally high speci-
ficity [41,42] but may precede tumor development by years [43].
4.4. Distribution of Second Primary Tumors over Time
Tumor follow-up was conducted over an average of 4.76 years after diagnosis, which
is in line with other studies on the same topic [5]. Still, our cohort contained patients that
were observed over 17 years.
As Kreimer et al. [43,44] found in serologic studies, more than 10 years can elapse
between HPV infection and the appearance of oropharyngeal cancer.
From Figure 1, we find that the majority of SPT occurred metachronously; in particular,
SPT of HPV-positive OPSCC. HPV-positive metachronous tumors were detected an average
of 42.13 months later than HPV-negative ones, and two of the SPT did not appear until
more than 13 years after diagnosis of the index tumor. Thus, it seems important to maintain
follow-up over time, especially for HPV-positive OPSCC. To determine SPT risk at different
points in time after diagnosis of the index OPSCC, studies with long-term follow-up of
larger cohorts than ours are needed.
4.5. Prognostic Impact of SPT
The Kaplan–Meier plot in Figure 2 shows a significantly higher survival rate of HPV-
positive patients compared to HPV-negative patients. This is consistent with the results of
many studies and with the landmark paper by Ang et al. [45]. They showed a more than
50% lower mortality risk in HPV-positive versus HPV-negative OPSCC patients.
Looking at the impact of SPT on the prognosis of OPSCC patients, the consensus in
the literature is the following: despite advances in therapy, the survival rate of OPSCC
patients remains reduced, especially if SPT are developed [24,46]. Bhattacharyya and
Nayak [47] found an up to 50% decreased survival rate in HNSCC patients with SPT
compared to HNSCC patients without SPT. Milliet et al. [36], on the other hand, did not
find a difference in overall survival between patients with and without SPT. In line with
the results of Bhattacharyya and Nayak [47], our cohort also showed significantly worse
survival of patients with SPT compared to patients without SPT. An analogous result was
observed when looking at HPV-negative patients only, who showed significantly worse
survival rates when SPT occurred (Figure 3). These findings were confirmed by the results
of Martel, etal[15] , In contrast, in HPV-positive OPSCC patients, survival with SPT did
not significantly differ from survival without SPT (Figure 3). The fact that survival in
HPV-positive patients does not significantly worsen with the occurrence of SPT may be
due to the better treatment response of HPV-positive tumors, as it has been shown in
HPV-positive index tumors [48,49]. To our knowledge, no comparable study of survival
with and without SPT has been published so far.
4.6. Strenghts and Limitations of the Study
This study is limited by the small number of cases for analysis of SPT. Since SPT
are much less frequent in HPV-positive OPSCC than in HPV-negative OPSCC, we only
recorded eight SPT of HPV-positive OPSCC. Thus, conclusions about the frequencies of
specific SPT localizations are limited, but they provide a lead for larger prospective studies.
Retrospective analyses, as performed in this study, must be interpreted with caution
due to the limited quality of retrospectively collected data, sample size limitations, and the
potential for noncontrolled influencing factors.
Although this study focused on SPT of HPV-associated OPSCC, HPV status of the
SPT was concluded solely based on the location and the HPV status of the index OPSCC.
Therefore, uncertainty remains regarding the HPV status of SPT. The possibility remains,
especially with tumors of the lung, that SPT are actually single metastases. Absolute
certainty in this regard can only be obtained by genetic sequence analysis, which was not
investigated in this study.
A strength of our study is the long observation period of up to 17 years.
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5. Conclusions
HPV-positive OPSCC showed a lower risk of SPT than HPV-negative OPSCC. SPT
of HPV-negative OPSCC occurred in the typical tobacco- and alcohol-associated sites.
Significantly more HPV-negative patients died from index OPSCC or its SPT than HPV-
positive patients. Thus, HPV positivity is a positive prognostic factor not only in the context
of overcoming cancer but also in terms of long-term survival. Since SPT of HPV-positive
OPSCC still occurred after more than 10 years, follow-up should not be reduced despite
the lower SPT risk of HPV-positive OPSCC.
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